Randomized, Single-Blind Study to Evaluate the Pharmacokinetics, Biomarkers, Safety and Tolerability of STAT-205 in Adult Patients With Mild COVID 19 Who Are at High Risk of Disease Progression
Latest Information Update: 06 Dec 2023
At a glance
- Drugs Naltrexone (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Statera BioPharma
- 02 Mar 2022 According to a Statera Biopharma media release, the Company expects to conclude enrollment during the third quarter and report topline results in the fourth quarter.
- 02 Mar 2022 According to a Statera Biopharma media release, this study is halfway through its enrollment of 24 patients.
- 20 Dec 2021 According to a Statera Biopharma media release, the first patient was dosed in this trial. The company expects preliminary trial results to be reported in 2022